IGHE and plasma cell myeloma: In a mouse model of orthotopic multiple myeloma created using CD138-positive U2661B1 cells, which produce human IgE lambda light chain (monoclonal protein), IV administration of NK012 was able to suppress plasma elevation of human monoclonal protein levels and proliferation of CD138-positive myeloma cells in mouse bone marrow in a dose-dependent manner [150].